Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07123090) titled 'A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma' on Aug. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Stephanie Berg
Condition:
Metastatic Renal Cell Carcinoma
Metastatic Renal Cancer
Renal Cell Carcinoma
Advanced Clear Cell Renal Cell Carcinoma
Kidney Cancer
Translocation Renal Cell Carcinoma
Intervention:
Drug: Sasanlimab
Drug: Palbociclib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 2026
...